Sakao Yukinori, Tomimitsu Shinji, Takeda Yuji, Natsuaki Masafumi, Itoh Tsuyoshi
Department of Thoracic and Cardiovascular Surgery, Saga Medical School of the University, Nabesima, 5-1-1, Saga 849-8501, Japan.
Eur J Cardiothorac Surg. 2004 Apr;25(4):520-2. doi: 10.1016/j.ejcts.2004.01.029.
To clarify the usefulness of measuring serum carcinoembryonic antigen (CEA) preoperatively to detect patients who will have a poor outcome after surgery, and who cannot be selected by conventional staging modalities.
One hundred patients with adenocarcinoma of the lung underwent standard surgical procedures between 1994 and April 2001 at our institution. Preoperative staging was assessed according to the TNM classification of the International Union Against Cancer. The associations between preoperative serum CEA level and the postoperative recurrence or lymph node metastasis were examined. The serum CEA level was classified into two groups according to concentration of CEA level: low (normal) CEA (<or=5.0 ng/ml) and high CEA (>5.0 ng/ml).
The high CEA level was associated with tumor relapse (P=0.01). According to the preoperative staging, the increased CEA was associated with tumor relapse only in stage C-IA (P=0.001). Stage C-IB and more advanced stages did not show an association between increased CEA and tumor relapse. In C-IA, risk for lymph node involvement was significantly higher in the high CEA group (4/9; 44.4%) than in the low CEA group (6/47; 12.8%, P=0.03). Furthermore, the rate of tumor relapse in C-IA-pN0 was significantly higher in the high CEA group (4 of the 5, 80%) than in the low CEA group (9 of the 41, 22.0%, P=0.018). The 5-year disease-free survival rate for patients with a high serum CEA level (N=9) was 22.2%, and 75.0% for patients with a normal CEA (N=47) level (P=0.0004).
Increased serum CEA is an important predictive factor for poor outcome after surgery in early-stage (C-IA) lung adenocarcinoma.
明确术前检测血清癌胚抗原(CEA)对于发现术后预后不良且无法通过传统分期方式筛选出的患者的有用性。
1994年至2001年4月期间,100例肺腺癌患者在本机构接受了标准外科手术。术前分期根据国际抗癌联盟的TNM分类进行评估。检测术前血清CEA水平与术后复发或淋巴结转移之间的关联。血清CEA水平根据CEA浓度分为两组:低(正常)CEA(≤5.0 ng/ml)和高CEA(>5.0 ng/ml)。
高CEA水平与肿瘤复发相关(P = 0.01)。根据术前分期,CEA升高仅在C-IA期与肿瘤复发相关(P = 0.001)。C-IB期及更晚期阶段未显示CEA升高与肿瘤复发之间存在关联。在C-IA期,高CEA组淋巴结受累风险(4/9;44.4%)显著高于低CEA组(6/47;12.8%,P = 0.03)。此外,C-IA-pN0期高CEA组肿瘤复发率(5例中的4例,80%)显著高于低CEA组(41例中的9例,22.0%,P = 0.018)。血清CEA水平高的患者(N = 9)5年无病生存率为22.2%,CEA正常的患者(N = 47)为75.0%(P = 0.0004)。
血清CEA升高是早期(C-IA)肺腺癌术后预后不良的重要预测因素。